All News
Combination treatments in Psoriatic Arthritis
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity. The standard practice is to use a conventional synthetic (csDMARD) with a bDMARD. The use of the combination of bDMARD with a tsDMARD such as a JAKi or TYK2i is a new order in the treatment of PsA.
Read Article
Health inequities in rheumatology: A central theme
This year at EULAR, health inequalities have taken centre stage as fundamental drivers of outcomes in rheumatic and musculoskeletal diseases. Across multiple sessions and studies, delegates are presenting compelling evidence and ground-breaking research demonstrating that who you are, where you live, and what resources you can access truly do shape the trajectory of chronic illness just as much as biological factors.
Read Article
1 shot will do!
#symptomatic #Knee #OA given #gene #therapy #intra-#articular
Seemed to last up to 104 weeks!
But no placebo
small safety study but sustained #WOMAC responses
Needs large #RCT but v interesting
#EULAR2025 @RheumNow @eular_org
Abst# POS0492 https://t.co/hqTqBorrbA
Links:
Janet Pope Janetbirdope ( View Tweet)
So much needed in SLE and pregnancy
1. Risk stratification at diagnosis
2. Pregnancy counseling at dx and >1 y before pregnancy
3. Close collab with GYN necessary
4. Challenging management given gaps in evidence.
#EULAR2025 #asktheexpert @RheumNow https://t.co/MXGkKpl452
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Pain & age predict outcomes in #osteoarthritis
In a #cohort of 92 pts with #knee #OA
Factors were studied for response
Better
✅#NSAIDs or #acetaminophen v #opiates
✅Older
✅Lower #WOMAC PAIN & no sensitization
🤔help RCT inclusion
#EULAR2025 @RheumNow POS0612 @eular_org https://t.co/9I2JN9sgUe
Janet Pope Janetbirdope ( View Tweet)
2025 EULAR/ACR Risk Stratification Criteria for At-Risk Arthralgia
A collaborative EULAR/ACR expert panel has established criteria for arthralgia patients at risk (clinically suspect arthralgia) to progress to chronic rheumatoid arthritis (RA). Risk stratification of CSA https://t.co/xbgJHhPqcq
Dr. John Cush RheumNow ( View Tweet)
Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS. https://t.co/E5jlYYHowM
Links:
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty
Dr. John Cush RheumNow ( View Tweet)
LIVE Daily Recap – EULAR 2025 Coverage
Date: Thursday, 06/12, Friday, 06/13 and Saturday, 06/14
Time: 12 (noon) ET
🔗 Tune in and join the conversation: YouTube, X, Facebook Live & LinkedIn
#RheumNow#EULAR25 #Rheumatology #MedTwitter #HCPs #RheumatologyEducation https://t.co/1qlcKDOL64
Dr. John Cush RheumNow ( View Tweet)
#Probiotics +#methotrexate giving far more #remission in #rheumatoid #arthritis than #MTX alone?
Seems fishy….
oops - #fish #oil #omega3 #fatty #acids do work!
not sure re the huge benefit of ‘immunebiotics’
#EULAR2025 @RheumNow @eular_org abst#POS0483 https://t.co/STQuaOkBcY
Janet Pope Janetbirdope ( View Tweet)
Closing the care divide in #JIA treatment plenary session
Overall theme in #EULAR2025 is everyone talking about AI and digital health on day 1
Biologics have changed the game!
@RheumNow https://t.co/qDqbz8JApe
Bella Mehta bella_mehta ( View Tweet)
#EULAR2025 Abstr#OP0077 Which MSK item/tool is important when assessing #SLE arthritis?Cohort study showed:
-SJC = good specificity. Correlated with US synovitis but not patient-defined response
-New tool, LAMDA correlated with US & patient response. May be used in RCT @RheumNow https://t.co/srVLKw2pcL
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Young Patients’ AREA empowers teens/young adults w/ autoimmune disease to shape research. US-based, youth-led & grounded in empowerment, they co-design studies, train peers & advise researchers. A truly positive and meaningful initiative esp for PPIE
@RheumNow #EULAR2025 #OP0008
Mrinalini Dey DrMiniDey ( View Tweet)
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy https://t.co/24e7wUV2FB
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Can RA be intercepted?
In the ALTO follow-up of the APIPPRA RCT (Cope et al), 1 year of abatacept delayed RA onset by up to 3 years in ACPA+/RF+ individuals. Effect strongest in those with mature autoantibody profiles.
Abstract#OP0004
@RheumNow #EULAR2025 https://t.co/N7YwtYod8w
Jiha Lee JihaRheum ( View Tweet)
If you successfully taper off DMARDs in RA patients in remission, do you risk bringing new joints in the mix?
Leiden post-hoc trial: these patients don’t do worse than those who never get off drug.
Drug-free remission tricky but new joints not a worry. #EULAR2025 @RheumNow https://t.co/QDxNRPN9f1
David Liew drdavidliew ( View Tweet)
In >228k CTD patients across France, ILD increased mortality risk across all CTDs. Proportion of incident CTD with ILD highest in IIM (37%). Up to 34% of CTD-ILD pts had progressive pulm fibrosis. Supports earlier ILD screening & vigilance in CTDs.
@RheumNow #EULAR2025 #OP0033 https://t.co/KkF9xFY4Cn
Mrinalini Dey DrMiniDey ( View Tweet)
Access inequity across Europe is real.
New #RheumaFacts data show major gaps in RMD care:
🔹 Full tsDMARD access in just 4% of countries
🔹 Self-referral possible in 57%
🔹 Rheum physio reimbursed in 63%
🔹 Psych care? Only 30%.
Abstract#OP0025
@RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
In #InflammatoryArthritis, baseline depression was linked to ↑ presenteeism & ↓ QoL at baseline + 3mo, but not absenteeism. Data from 9-country study provide further evidence that mental health is key to supporting work outcomes in RA, PsA & axSpA.
@RheumNow #EULAR2025 #OP0028
Mrinalini Dey DrMiniDey ( View Tweet)
STAMP RCT early SEC vs. SoC 120pts
Retention 58% vs 30%
ACR 20, 50, 70 and MDA: better outcome at Month 3 but no difference at Month 6
Dactylitis no difference
Of note here SoC was a tight T2T strategy!
@RheumNow #OP0092 #EULAR2025 https://t.co/8zHs5CRFV5
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
